CN102846549B - 一种土霉素脂质体的制备方法 - Google Patents
一种土霉素脂质体的制备方法 Download PDFInfo
- Publication number
- CN102846549B CN102846549B CN201210320457.1A CN201210320457A CN102846549B CN 102846549 B CN102846549 B CN 102846549B CN 201210320457 A CN201210320457 A CN 201210320457A CN 102846549 B CN102846549 B CN 102846549B
- Authority
- CN
- China
- Prior art keywords
- oxytetracycline
- liposome
- preparation
- carrying
- stirring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 235000019366 oxytetracycline Nutrition 0.000 title claims abstract description 62
- 239000004100 Oxytetracycline Substances 0.000 title claims abstract description 61
- 229960000625 oxytetracycline Drugs 0.000 title claims abstract description 61
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 title claims abstract description 61
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 title claims abstract description 61
- 239000002502 liposome Substances 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000000243 solution Substances 0.000 claims abstract description 23
- 238000003756 stirring Methods 0.000 claims abstract description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 19
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 12
- 239000012043 crude product Substances 0.000 claims abstract description 12
- 238000001914 filtration Methods 0.000 claims abstract description 7
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 6
- 238000001816 cooling Methods 0.000 claims abstract description 6
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 6
- 239000012528 membrane Substances 0.000 claims abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- 239000007979 citrate buffer Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 238000007670 refining Methods 0.000 claims description 7
- 229960004756 ethanol Drugs 0.000 claims description 6
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000012982 microporous membrane Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 9
- 238000005538 encapsulation Methods 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 abstract 2
- 230000002035 prolonged effect Effects 0.000 abstract 2
- 239000007853 buffer solution Substances 0.000 abstract 1
- 230000007012 clinical effect Effects 0.000 abstract 1
- 238000000703 high-speed centrifugation Methods 0.000 abstract 1
- 230000036571 hydration Effects 0.000 abstract 1
- 238000006703 hydration reaction Methods 0.000 abstract 1
- 238000009413 insulation Methods 0.000 abstract 1
- 238000011068 loading method Methods 0.000 abstract 1
- 238000002156 mixing Methods 0.000 abstract 1
- 230000010355 oscillation Effects 0.000 abstract 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 abstract 1
- 235000017557 sodium bicarbonate Nutrition 0.000 abstract 1
- 241000282898 Sus scrofa Species 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000003771 laboratory diagnosis Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000001572 Mycoplasma Pneumonia Diseases 0.000 description 1
- 241000204045 Mycoplasma hyopneumoniae Species 0.000 description 1
- 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 description 1
- 206010033971 Paratyphoid fever Diseases 0.000 description 1
- 241000269799 Perca fluviatilis Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000605008 Spirillum Species 0.000 description 1
- 241001275829 Squaliobarbus Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000010824 fish disease Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 208000008977 mycoplasmal pneumonia of swine Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940072172 tetracycline antibiotic Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210320457.1A CN102846549B (zh) | 2012-08-31 | 2012-08-31 | 一种土霉素脂质体的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210320457.1A CN102846549B (zh) | 2012-08-31 | 2012-08-31 | 一种土霉素脂质体的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102846549A CN102846549A (zh) | 2013-01-02 |
CN102846549B true CN102846549B (zh) | 2014-01-08 |
Family
ID=47393804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210320457.1A Expired - Fee Related CN102846549B (zh) | 2012-08-31 | 2012-08-31 | 一种土霉素脂质体的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102846549B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106496309A (zh) * | 2016-11-24 | 2017-03-15 | 北京开景基因技术有限公司 | 微球抗原及其制备方法以及抗可替宁抗体的制备方法 |
-
2012
- 2012-08-31 CN CN201210320457.1A patent/CN102846549B/zh not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
中国兽药典委员会.《土霉素,残留溶剂测定法》.《中华人民共和国兽药典》.2005,(第2005版),第14页,附录71. * |
王俊菊,曹鸿国.《兽药脂质体的制备和应用》.《动物科学与动物医学》.2003,第20卷(第12期),第28-29页. * |
Also Published As
Publication number | Publication date |
---|---|
CN102846549A (zh) | 2013-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102871996B (zh) | 一种抗菌药物组合物及其应用 | |
CN102697730A (zh) | 一种氟苯尼考可溶性粉及其制备方法 | |
CN106074543B (zh) | 一种含阿莫西林的水溶性增效组合物及其应用 | |
CN102846550B (zh) | 一种氟苯尼考脂质体的制备方法 | |
CN101756910B (zh) | 一种肺靶向头孢噻呋微球及制备方法 | |
CN104606218A (zh) | 一种治疗奶牛泌乳期乳房炎的乳房注入剂及其制备方法 | |
CN102846549B (zh) | 一种土霉素脂质体的制备方法 | |
CN106620668A (zh) | 一种复方替米考星固体分散剂及其制备方法 | |
CN102614294A (zh) | 一种复方阿莫西林混悬注射剂及其制备方法 | |
CN102824337A (zh) | 一种治疗家畜子宫内膜炎的凝胶剂及其制备方法 | |
CN102846548B (zh) | 一种沃尼妙林脂质体的制备方法 | |
CN103169652A (zh) | 一种兽用碱性林可霉素注射液及其制备方法和用途 | |
CN102600078B (zh) | 一种恩诺沙星脂质体的制备方法 | |
CN103877025A (zh) | 一种芬苯达唑可溶性粉及其制备方法 | |
CN102641241A (zh) | 一种盐酸沙拉沙星混悬乳剂及其制备方法 | |
RU2652276C1 (ru) | Способ лечения послеродового эндометрита у коров | |
CN100425229C (zh) | 含有抗感染药物组合物的局部药用制剂及其制备方法 | |
CN105232464A (zh) | 一种盐酸环丙沙星脂质体制剂及其制备方法 | |
CN104622803A (zh) | 一种治疗泌乳期奶牛乳房炎的乳房注入剂及制备方法 | |
CN108403631A (zh) | 酒石酸泰万菌素油混悬注射剂及其制备方法 | |
CN104288152A (zh) | 一种兽用复方硫酸小檗碱注射剂及其制备方法 | |
CN105726462A (zh) | 一种复方普鲁卡因青霉素奶牛乳房注入剂(干乳期) | |
CN102274221B (zh) | 一种兽用复方利福昔明脂质体药物及其制备方法 | |
CN103202846B (zh) | 一种兽用盐酸恩诺沙星、盐酸多西环素纳米乳液及其制备方法 | |
RU2471359C1 (ru) | Способ коррекции иммунобиологических показателей у поросят в период отъема |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Shu Wendai Inventor after: Xu Jin Inventor after: Guo Junqing Inventor after: Li Jianzheng Inventor before: Wu Hongyun Inventor before: Xu Jin Inventor before: Guo Junqing Inventor before: Li Jianzheng |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WU HONGYUN XU JIN GUO JUNQING LI JIANZHENG TO: SHU WENDAI XU JIN GUO JUNQING LI JIANZHENG |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: 451162 Zhengzhou economic comprehensive experimentation area, Zhengzhou air port, Henan, Xingang Province Patentee after: Henan Hou Yi Industry Group Co., Ltd. Address before: 451162 Xingang, Henan, Zhengzhou, Hong Kong airport on the eastern side of the road on the eastern side of Zhengzhou Patentee before: Zhengzhou Houyi Pharmaceutical Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140108 Termination date: 20200831 |